February 24, 2022
Date: Feb 24, 2022
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Kathleen Kenney, Associate Director, Viral Clearance, WuXi Advanced Therapies, R. Christopher Manzari, Manager, Viral Clearance – DSP/Virus Production, WuXi Advanced Therapies.
Join us for a discussion on the risk-based approach in the development of Viral Validation studies, a key testing requirement for regulatory submissions of viral vector-based therapeutics, at WuXi Advanced Therapies. In this webinar, members of the Viral Clearance Management team will cover the basics of viral clearance, study development and the general timeline. Collaboration between the sponsor and WuXi Advanced Therapies team ensures that our studies maximize the potential viral log reduction possible while reducing the number of steps for evaluation. Additionally, learn about WuXi Advanced Therapies’ option to perform your studies remotely through our Validation on Demand team so that travel to our site is not needed.
In this webinar, you will learn:
A general overview of why viral clearance studies are performed.
Viral clearance study design at WuXi Advanced Therapies.
WuXi Advanced Therapies’ unique approaches to maximize your total viral reduction in fewer steps.
Just fill out the form below to watch the recorded webcast now.
You May Also Like
